Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $5.0B | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B | $1.9B | $1.5B | $1.0B | $718M | $573M | $402M | $259M | $160M | $100M | $76M | $49M | $30M | $10M | $5M | $2M |
| Bruttoergebnis | $3.1B | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B | $1.3B | $932M | $664M | $492M | $378M | $278M | $176M | $100M | $47M | $36M | $18M | $4M | ($6M) | ($8M) | ($9M) |
| Bruttomarge % | 62.8% | 60.0% | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% | 63.1% | 64.4% | 68.5% | 66.0% | 69.2% | 68.0% | 62.6% | 46.7% | 47.0% | 37.9% | 12.3% | -56.2% | -175.2% | -405.1% |
| Betriebsergebnis (EBIT) | $1.1B | $912M | $600M | $598M | $391M | $266M | $300M | $142M | ($186M) | ($42M) | ($64M) | ($57M) | ($22M) | ($29M) | ($56M) | ($45M) | ($45M) | ($46M) | ($53M) | ($47M) | ($49M) |
| Operative Marge % | 22.9% | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | 15.5% | 9.6% | -18.1% | -5.9% | -11.2% | -14.2% | -8.3% | -18.1% | -55.8% | -58.8% | -93.1% | -154.4% | -537.0% | -1008.8% | -2273.0% |
| Jahresüberschuss | $1.0B | $836M | $576M | $542M | $341M | $217M | $494M | $101M | ($127M) | ($50M) | ($66M) | ($58M) | ($22M) | ($30M) | ($54M) | ($45M) | ($55M) | ($54M) | ($55M) | ($46M) | ($47M) |
| Nettomarge % | 20.1% | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 25.6% | 6.9% | -12.3% | -7.0% | -11.4% | -14.3% | -8.6% | -18.6% | -54.5% | -58.7% | -113.5% | -180.3% | -560.9% | -991.5% | -2147.6% |
| EBITDA | — | $1.4B | $946M | $917M | $565M | $378M | $377M | $213M | ($75M) | ($20M) | ($49M) | ($46M) | ($13M) | ($22M) | ($49M) | ($41M) | ($51M) | ($43M) | ($50M) | ($43M) | ($47M) |
| Ergebnis je Aktie (EPS) | $2.52 | $2.06 | $1.40 | $1.27 | $0.80 | $0.51 | $1.27 | $0.27 | $-0.36 | $-0.15 | $-0.20 | $-0.18 | $-0.07 | $-0.10 | $-0.20 | $-0.17 | $-0.24 | $-0.30 | $-0.47 | $-0.41 | $-0.43 |
| Ausstehende Aktien (Mio.) | — | 406M | 413M | 426M | 428M | 429M | 390M | 369M | 353M | 345M | 334M | 319M | 301M | 284M | 275M | 262M | 228M | 177M | 118M | 113M | 109M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für DXCM. /companies/us/DXCM
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms